Indegene Limited · NSE:INDGN
Indegene — Q3 FY2025 Earnings Presentation
20 slides from Indegene's earnings presentation, January 2025
Slide 1: Investor Presentation
Investor Presentation January 2025
Slide 2: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 3: We operate at the intersection of healthcare and technology
We operate at the intersection of healthcare and technology Healthcare Tech-Led Expertise Delivery and Healthcare market Digital understanding Capabilities Digital-first approach In-depth domain Gen AI based tools and platform knowledge Navigating regulatory landscape Drive transformation Medical co
Slide 4: We are a Digital First Commercialization Partner
We are a Digital First Commercialization Partner We Provide Capabilities and Expertise Across the Commercialization Value Chain Regulatory and R&D / Clinical Marketing and Sales Pharmacovigilance Medical Affairs and Others Brand Strategy and Pharmacovigilance Digital content Medical content Patient
Slide 5: Our large addressable market is underpinned by growing outsourcing and rapid digital adoption
Our large addressable market is underpinned by growing outsourcing and rapid digital adoption Large Market Opportunity Outsourcing and Tech Lifesciences at Inflection We Offer Solutions Expanding our TAM Point Across Life Sciences Life Sciences Operations Spend Across End Markets Verticals ($B) Pate
Slide 6: Management Commentary on Q3FY25 results
Management Commentary on Q3FY25 results Manish Gupta Suhas Prabhu Chairman and Chief Executive Officer Chief Financial Officer “We have consistently grown our revenue, maintaining stable and “Q3FY25 was another successful quarter for Indegene. We improved our profitable growth, and our Q3FY25 number
Slide 7: Q3 FY25: Business Highlights
Q3 FY25: Business Highlights Significant INR 7,204 Mn 7.0% 4.9% growth at scale Revenue from Operations YoY revenue growth QoQ revenue growth in INR terms in INR terms 20.8% 15.2% Strong EBITDA Margin PAT Margin margin profile 2.4pp QoQ 1.9pp QoQ © 2025 Indegene. All rights reserved. 7
Slide 8: Q3 FY25: Business Highlights
Q3 FY25: Business Highlights Strong client 75 38 64% relationships Active Client Relationships Clients with $1 Million+ Revenue from Top 20 Global Revenue Biopharma Companies (1) Global 4,880/4,198 23.3% 17.3% Delivery Total Employees / Delivery Employees Delivery Headcount with Voluntary Attrition
Slide 9: Q3 FY25: Business mix
Q3 FY25: Business mix Revenue from Service offering ($Mn) Revenue by Customer Industry (%) Revenue by Customer Geography (%) 1.2% 80.9 82.0 85.2 2.6% 2.5% 5.8% 3.4% 3.5% 13.7% 11.6% 12.4% 2.3% 27.9% 69.3% 0.5% 56.2% 55.6% 57.9% 28.8% 28.5% 93.7% 22.6% Q3FY24 Q2FY25 Q3FY25 Q3FY25 Q3FY25 Enterprise Me
Slide 10: Q3 FY25: Segment Performance Update
Q3 FY25: Segment Performance Update Segment performance QoQ Segment performance YTD 3,863 4,003 11,36011,615 1,977 2,052 5,918 4,406 1,088 794 798 889 230 260 2,312 2,510 ENTERPRISE ENTERPRISE MEDICAL OMNICHANNEL OTHERS ENTERPRISE ENTERPRISE MEDICAL OMNICHANNEL OTHERS COMMERCIAL ACTIVATION COMMERCIA
Slide 11: Growth Approach 1: Deeper Engagement with Large Pharma Customers
Growth Approach 1: Deeper Engagement with Large Pharma Customers Revenue from Top 5 customers Revenue from Top 20 customers 11,345 11,984 11,218 21,657 21,927 19,321 9,176 14,320 FY22 FY23 FY24 LTM - Q3FY25 FY22 FY23 FY24 LTM - Q3FY25 • Continued growth in the largest customer • Good opportunities f
Slide 12: Growth Approach 2: Broader targeting leading to a wider, taller pyramid
Growth Approach 2: Broader targeting leading to a wider, taller pyramid 75 29 10 Active clients(1) Active clients (1) Incremental clients successfully grown to added FY22 to Q3FY25 $Mn+ category from FY22 to Q3FY25 Growing active client base(1) # Successful track record of growing accounts # 38 36 3
Slide 13: Financial Highlights
Financial Highlights © 2025 Indegene. All rights reserved. 13
Slide 14: Q3 FY25 Consolidated Financials
Q3 FY25 Consolidated Financials Amount in INR Mn Particulars Q3 FY25 Q2 FY25 Q3 FY24 QoQ % YoY% 9M FY25 9M FY24 YoY% Revenue from Operations 7,204 6,868 6,734 4.9% 7.0% 20,837 19,166 8.7% Employee Benefit Expenses 4,438 4,420 4,131 0.4% 7.4% 13,301 12,232 8.7% Other Expenses 1,448 1,187 1,114 22.0%
Slide 15: Healthy margin profile and robust balance sheet
Healthy margin profile and robust balance sheet EBITDA and EBITDA Margin PAT and PAT Margin Cash and Cash Equivalent(1) INR Mn and % INR Mn and % INR Mn 22.3% 20.8% 15.2% 14.7% 18.4% 13.4% 14,666 15,079 1,499 1,501 1,097 988 1,267 917 9,521 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3F
Slide 16: Indegene Digital Summit 2024
Indegene Digital Summit 2024 • Sixth edition, with 50+ industry- leading speakers • Featured practitioners' perspectives on Generative AI, Advanced Analytics, Technology and Operations Transformation • One of the most anticipated annual events in life sciences globally • Promotes idea exchange, coll
Slide 17: Awards and Recognitions
Awards and Recognitions People Business Consulting: Top 50 Companies with Great Managers in India People Business Consulting: Top 100 Great Managers in India © 2025 Indegene. All rights reserved. 17
Slide 18: Thank You!
Thank You! www.indegene.com
Slide 19: Fact Sheet
Fact Sheet Consolidated Financial Data - Third Quarter, Fiscal 2025 Operational & Financial Metrics Key performance indicators (in INR Mn) Quarter ended Growth SI. Particulars Dec 31, Sept 30, Dec 31, No. YoY QoQ 2024 2024 2023 1. Active clients(1)(No.) 75 68 65 2. Revenue from operations 7,204 6,86
Slide 20: Fact Sheet
Fact Sheet Consolidated Financial Data - Third Quarter, Fiscal 2025 Revenue by customer industry (in %) Quarter ended (contribution) Growth Particulars Dec 31, Sept 30, Dec 31, YoY QoQ 2024 2024 2023 Biopharma 93.7 94.1 93.9 6.7 4.5 Medical Devices 2.6 2.4 2.8 -1.2 16.8 Emerging Biotech 2.5 2.6 2.5